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Abstract
A case of a child presenting with congenital abnormalities at 
birth is reported. The early development remained severely 
retarded and acquired skills minimally. The head circumfer­
ence centile decreased. Magnetic resonance imaging 
showed progressive neuronal atrophy and secondary delay 
in myelination. Dihydropyrimidine concentrations in body 
fluids were quantitated by NMR spectroscopy. Enzymatic 
assay in the liver biopsy revealed total deficiency of dihy­
dropyrimidinase (DHP) (5,6-dihydropyrimidine amidohydro- 
lase; EC J.5.2.2). As such, the patient is the first with
enzymatically proven DHP deficiency. Thus far dihydropy- 
rimidmuria has been reported in three other patients with a 
variety of neurological abnormalities. A relation of the en­
zyme deficiency with the neurodegenerative clinical course 
in our patient is suggested.
Key words: Dihydropyrimidinuria -  Dihydropyrimidinase 
deficiency -  5,6-dihydropyrimidine amidohydrolase -  Neu­
rodegenerative disease -  NMR spectroscopy
Introduction
Dihydropyrimidinase (5,6-dihydropyrimidine amidohydrolase; 
EC 3.5.2 .2) is the second enzyme involved in the breakdown of 
the pyrimidine bases uracil and thymine. It catalyses the degra­
dation of dihydrouracil to B-ureidopropionic acid and dihy- 
drothymine to B-ureidoisobutyric acid (Fig. 1). The first case of 
diliydropyrimidinuiia in humans has been reported by Duran et 
al in an infant presenting with convulsions (4, 5). Otherwise, the 
child had a normal development at 19 months. Henderson et al 
subsequently described an infant with DHP deficiency and severe 
developmental delay (8). hi Japan a case with dihydropyrimidi­
nuria was detected within a metabolic screening program in a 
healthy girl, 6 months of age (9), The suspected enzymatic 
deficiency of dihydropyrimidinase in these cases has as yet not 
been confirmed. We present a new case with enzymatically 
proven DHP-deficiency with severe neurological symptoms. 
Quantification of the relevant metabolites in urine, plasma and 
CSF was done by H-NMR spectroscopy
Case
Clinical presentation
The patient, a girl, was the first child of healthy consanguineous 
parents (first cousins) from Morocco. The family history did not 
reveal hereditary neurological disorders. Pregnancy and delivery 
were unremarkable. On investigation at birth dysmorphic fea­
tures were noted: plagiocephaly, an anteriorly displaced anus, 
short perineum and open anovestibular fistula, clubfoot at the 
right and hip lateralization at the left side, hypoplasia of the end
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phalanges and nails of the third finger and toe. Furthermore 
facial dysmorphic features such as coarse face, cupped ears and a 
broad nasal bridge were noted. Bodyweight at birth was 3590 
gram, length was 50 cm. Apgar scores were 7 and 8 at 0 and 5 
min, respectively She had feeding difficulties shortly after birth. 
Colostomy was carried out because of the anorectal abnormality.
Between the age of 3 and 26 months she was hospitalized on 
several occasions for surgical interventions and for neurological 
and metabolic evaluation in view of her severe developmental 
delay and convulsions. No organomegaly was present. Cardiac 
examination was normal Length and weight followed the 80th 
centile. The head circumference decreased slowly in 2 years from 
the 60th centile to the 30th centile, Mental development was 
absent. Visual fixation occurred sporadically after the age of one
V
Fig. 1 Scheme of pyrimidine degradative pathways
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Fig. 2 Relevant parts from 500 MHz NMR spectra of urine (A) and CSF (B) of the patient.
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year. Auditory reactions were absent except for reflex myoclonic 
reactions after one year. Myoclonic seizures were no Led since the 
age of 3 months, Pupillary hippus was often the only, but 
persisting epileptic phenomenon. Repeated fundoscopic exami­
nation revealed disc pallor suggestive for hypomyelination. Bul­
bar reflexes were absent or decreased interfering with efficient 
feeding. The motor performance was predominantly choreatic. 
Gradually pyramidal signs appeared. The tone was always de­
creased to severe floppiness resulting in frog position and head- 
lag.
Additional examinations
Laboratory
Routine biochemical and haematological investigations were 
normal, except for a persisting and unexplained increase of 
alkaline phosphatase (700 U/l to 1700 U/l; normal value: 
< 120  U/l), but normal gammaGT, ALAT and AS AT Chromo­
somes were 46 XX in blood and fibroblasts. Spinal fluid exam­
ination was within normal limits, including amino acids and 
brain-specific proteins (S-100, myelin basic protein and neuron 
specific enolase). Urine analysis for mucopolysaccharides, oligo­
saccharides, monosaccharides and polyols, and neuraminic acid 
was normal. Analysis of the lysosomal enzymes in the leukocytes
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Table 2 Clinical presentation and 
degree of dihydropyrimidinuria.
• * » « » •  »•> » > » » • • ri44 • * —
Patient Sex Age Presentation and course Dihydropyrimidinuria
referen­ Dihydrouracil Dihydrothymine
ces
4, 5 M 8 wk Seizures HPLC*: 790 450 (.imol/L
Normal development
Lost for follow-up
9 F 11 mnth Screening program, normal infant HPLC*: 626 451 |.imol/mmol creat.
No follow-up
8 M 6 wk Febrile seizures at 6 weeks HPLC*: 100-500 nmol/mmol
Intractable seizure disorder 100-500 creat.
Cross microcephaly 
Severe mental retardation 
Spastic quadriplegia, choreatic signs 
Lost for follow-up
Case F birth Dysmorphic features (see above) 
Intractable seizure disorder 
Severe developmental delay 
Feeding problems
Decrease centile head circumference 
Pyramidal/choreatic signs and symptoms 
EEG, EPs, MRI: progressive disease 
Follow-up: birth-onward
H-NMR**: 760 490 f.imol/mmol creat
*  
*  *
HPLC, high pressure liquid chromatography 
H-NMR, NMR spectroscopy (Table 1)
the age of 8 weeks. She showed subsequently a normal develop­
ment up to the age of 19 months. The second case reported by 
Henderson et al (8) however, presented with febrile convulsions at 
() weeks and subsequent frequent generalized seizures. On ex­
amination at 2 V '2 years of age, gross microcephaly and severe 
developmental retardation were noted. Signs of spastic quadri­
plegia and jerky choreiform movements were observed. The third 
case (9) was discovered in a screening program for inborn errors 
of pyrimidine metabolism. The case showed no neurological 
symptoms at the time of diagnosis at the age of 11 months. 
Our case is remarkably similar to the one described by Henderson, 
but our patient showed more clearly clinical, neurophysiological 
and MRI features of a progressive neurodegenerative disease. 
Clinically there were lack of menial development, decreasing 
head circumference, a progressive seizure disorder and choreat­
ic-pyramidal features. The evoked potential studies were con­
current with a retarded central conduction and maturation, and 
the EEG investigations pointed to deterioration, both with 
respect to the general background activity as to the nature of 
the irritative paroxysmal activity. The repeated MRIs were con­
sistent with primary neuronal degeneration with secondary re­
tarded myelination.
The differing severity of the neurological symptoms suggests that 
phenotypic expression might be broad, as can be seen in the other 
pyrimidine disorder, i.e. dihydropyrimidine dehydrogenase defi­
ciency (2, 7). Furthermore, in our patient we are dealing with a 
complete deficiency of the enzyme, while in the other cases the 
deficiency has not yet been established on the enzymatic level. A 
relation of the degree of enzyme deficiency and the clinical 
presentation is currently not available.
The pathophysiological mechanism involved in the occurrence of 
neurological signs and symptoms in patients with pyrimidine 
disorders is unclear. In our patient the concentration of the two 
dihydropyrimidines was significantly higher in the CSF than in 
blood. This can be explained by active transport of dibydropyr­
imidines from blood to CSF over the blood-brain barrier. How­
ever, no transporters for these compounds are known. It is more 
likely that within the brain active biosynthesis of B-alanine and
possibly also of B-aminoisobutyric acid occurs from uracil and 
thymine, respectively DcFeudis and Martin Del Rio have empha­
sized the importance of B-alanine as a putative neurotransmiUer 
(3). From animal studies it appears that 6-alanine acts, together 
with glycine and GAB A, as inhibitory amino acid mainly in the 
spinal cord, but also in cerebral cortical membranes (11). If B- 
alanine plays a pathophysiological role, it should exert besides 
inhibitory also neuromodulatory functions in the infant brain, in 
view of the cerebral development in our patient. The clinical 
symptomatology in our patient is probably too complex to be 
explained only by decreased B-alanine inhibition.
Furthermore, it has been described that uridine has anticonvul­
sant effects in animals with experimental seizures (10). This 
might indicate that pyrimidine compounds play a role in the 
regulation of central nervous system activity. Moreover, in cancer 
treatment, disturbances of pyrimidine metabolites by antimeta­
bolites are thought to be responsible for ncurotoxicity (14).
Our finding of higher dihydropyriniidine concentrations in the 
CSF than in plasma may be the beginning of an explanation for 
involvement of the CNS in DHP-deficiency. It remains unknown 
whether the low concentration of B-alanine or the high concen­
tration of the dihydropyrimidines is the most important factor for 
the clinical symptomatology. The as yet unknown metabolite 
observed only in the CSF of our patient may be of interest in this 
respect. It has not been confirmed in another case if this 
metabolite relates to DHP-deficiency.
These arguments support the hypothesis that inborn errors of 
pyrimidine metabolism are associated with central nervous sys­
tem dysfunction and disease. Further enzymatic and genetic 
studies are needed to explain the variability of the clinical 
expression of dihydropyrimidinase deficiency.
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